The sphingosine-1-phosphate receptor: A novel therapeutic target for multiple sclerosis and other autoimmune diseases - ScienceDirect
Novel mechanism and biomarker of chronic progressive multiple sclerosis - Oki - 2018 - Clinical and Experimental Neuroimmunology - Wiley Online Library
Mechanism of action of s1p receptor modulators in multiple sclerosis: The double requirement - ScienceDirect
Mechanism of Action | MAYZENT® (siponimod)
Sphingosine 1-Phosphate Receptor Modulators for the Treatment of Multiple Sclerosis. - Abstract - Europe PMC
Mechanism of Action | MAYZENT® (siponimod)
Disease-Modifying Therapies (Chapter 7) - Multiple Sclerosis
Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects | SpringerLink
Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond | Nature Reviews Drug Discovery
Siponimod (BAF312) Treatment Reduces Brain Infiltration but Not Lesion Volume in Middle-Aged Mice in Experimental Stroke | Stroke
Sphingosine-1-Phosphate Modulators for Multiple Sclerosis - Practical Neurology
Siponimod (Mayzent) Downregulates RhoA and Cell Surface Expression of the S1P1 and CX3CR1 Receptors in Mouse RAW 264.7 Macrophages | SpringerLink
Proposed mode of action of siponimod: Schematic illustrating our... | Download Scientific Diagram
Mayzent: New Drug for Treatment of Secondary Progressive Multiple Sclerosis | BioPharma Media
Siponimod - an overview | ScienceDirect Topics
Mayzent: New Drug for Treatment of Secondary Progressive Multiple Sclerosis | BioPharma Media
Targeting the S1P receptor signaling pathways as a promising approach for treatment of autoimmune and inflammatory diseases - ScienceDirect
Sphingosine 1-Phosphate Receptor Modulators for the Treatment of Multiple Sclerosis. - Abstract - Europe PMC
JCI Insight - Siponimod enriches regulatory T and B lymphocytes in secondary progressive multiple sclerosis
Progressive multiple sclerosis: from pathophysiology to therapeutic strategies | Nature Reviews Drug Discovery
Frontiers | Sphingosine 1-Phosphate Receptors and Metabolic Enzymes as Druggable Targets for Brain Diseases | Pharmacology
Current immunotherapies for multiple sclerosis and neuromyelitis optica spectrum disorders: the similarities and differences
Novartis's Siponimod Genentech's Ocrevus Challenges Outlook For The Progressive MS Market
